An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study. - Sorbonne Université Access content directly
Journal Articles Lung Cancer Year : 2007

An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.

Hervé Lecaer
  • Function : Author
Fabrice Barlesi
Gilles Robinet
  • Function : Author
Laurence Geriniere
  • Function : Author
Pierre Bombaron
  • Function : Author
Lionel Falchero
  • Function : Author
Jean Baptiste Auliac
  • Function : Author
Jacky Crequit
  • Function : Author

Abstract

CONTEXT: The objective of this study was to evaluate the feasibility and activity of weekly docetaxel monotherapy in frail elderly patients with advanced-stage non-small-cell lung cancer, selected on the basis of their precise age, general condition, and number of comorbid disorders (Charlson score). METHODS: Analysis of the response rate, toxicity, quality of life, median survival and 1-year survival rates after 1-3 six-week cycles of docetaxel 30mg/m(2) weekly. RESULTS: Fifty patients were enrolled and 42 were assessable. Five patients (10%, [3.7-22.6]) had objective responses, 14 (28%, [16.9-41.6]) had stable disease, and 23 (46%, [32.6-52.8]) progressed. The main grade 3-4 toxicity was fatigue (30%). Quality of life remained stable during treatment. The median survival time was 4.3 months, and the 1-year survival rate was 21.8%. CONCLUSION: In frail elderly patients selected on the basis of their age, general condition and comorbidity, weekly docetaxel monotherapy has acceptable toxicity and does not negatively affect quality of life. In contrast, it has only moderate activity.

Dates and versions

hal-00597131 , version 1 (31-05-2011)

Identifiers

Cite

Hervé Lecaer, Fabrice Barlesi, Gilles Robinet, Pierre Fournel, Laurence Geriniere, et al.. An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.. Lung Cancer, 2007, 57 (1), pp.72-8. ⟨10.1016/j.lungcan.2007.02.012⟩. ⟨hal-00597131⟩
83 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More